Benefits
Joint pain fell in a small uncontrolled pilot
In an 8-week uncontrolled pilot, 29 exercise-trained men took Cissus quadrangularis 3,200 mg/day with no placebo group. Self-reported joint pain (WOMAC) fell by about 31% from baseline, but with no control arm this cannot be separated from natural variation or expectation. The authors themselves called for a placebo-controlled trial to confirm it, and no clinical measures (blood pressure, biomarkers) changed.
Weight management: 123-subject formulation trial
In a double-blind randomized trial in 123 overweight and obese adults, a proprietary Cissus quadrangularis formulation (not isolated Cissus) reduced body weight, central obesity, fasting glucose, cholesterol and triglycerides versus placebo over 8 weeks. Because the product was a multi-ingredient formulation and the trial came from a single industry-linked group that has not been independently replicated, the effect cannot be attributed to Cissus alone and should be read as preliminary.
Bone fracture healing acceleration
Cissus quadrangularis has a long traditional use for bones and fractures, reflected in its name 'Hadjod' (bone-setter). Direct human fracture-healing evidence is limited and low quality (older, mostly small or uncontrolled reports), and the supporting bone mechanisms come largely from animal and cell studies, so accelerated fracture healing is not established in modern controlled trials.
Postmenopausal bone density: no change versus placebo
In a randomized placebo-controlled trial, 134 postmenopausal women with osteopenia took Cissus quadrangularis (1.2 or 1.6 g/day) or placebo for 24 weeks. Bone mineral density did not differ from placebo at any site. The only change was a fall in a bone-formation marker (P1NP), which suggests slower bone remodeling but is a laboratory surrogate, not a measured gain in bone density.
Anti-inflammatory pathway support
Cissus quadrangularis inhibits COX-2 and 5-LOX enzymes — the major inflammatory pathway enzymes. Combined inhibition addresses both prostaglandin and leukotriene inflammatory mediators. Mechanism is broader than typical NSAIDs (which primarily target COX pathways). Reduced inflammation drives the joint pain reduction and broader anti-inflammatory effects.
Weight loss synergy with African mango
In a 10-week trial from the same research group (72 participants), a Cissus plus Irvingia gabonensis combination reduced weight and body fat more than placebo, and somewhat more than Cissus alone. Because this is a combination product, the larger effect cannot be attributed to Cissus, and the very large weight changes reported by this single group have not been independently replicated.
Metabolic syndrome multi-marker improvement
The metabolic changes reported for Cissus (weight, glucose, lipids) come from a small number of trials by a single industry-linked group that have not been independently replicated, and mostly tested a proprietary formulation or a Cissus plus Irvingia combination. They should be treated as preliminary rather than as established cardiovascular or metabolic-syndrome benefits.
Appetite suppression and digestive interaction
Researchers believe Cissus helps achieve weight loss by suppressing appetite, reducing food consumption, and interacting with enzymes that digest fats and sugar. Multiple mechanisms supporting weight management vs single-mechanism alternatives. Appetite suppression supports sustained dietary compliance.
Rapid-onset and sedative claims are not established
Claims that Cissus acts within 30 minutes or has sedative and muscle-relaxing effects are not supported by the human trials cited here, which measured joint pain, weight and bone markers over weeks, not acute effects. Treat rapid-onset and sedative claims as unverified.
Mechanism of action
COX-2 and 5-LOX inflammatory enzyme inhibition
Cissus quadrangularis inhibits both cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) inflammatory pathway enzymes. Dual pathway inhibition addresses both prostaglandin (COX) and leukotriene (LOX) inflammatory mediators. More comprehensive anti-inflammatory profile than typical NSAIDs targeting only COX.
Ketosterone bone-promoting bioactivity
Ketosterones (also called ketosteroids) are the marker bioactives in standardized Cissus extracts. In preclinical work these steroid-structure compounds have been linked to bone protein synthesis. This is a proposed mechanism: the one human bone-density RCT (Benjawan 2022) found no change in bone mineral density versus placebo, so a bone-preservation effect is not established in people.
IGF (Insulin-like Growth Factor) increase
Some preclinical work reports that Cissus quadrangularis can raise IGF (insulin-like growth factor). This is a laboratory and animal finding that has not been shown to translate into measured bone or performance gains in people, so it should not be read as an established anabolic effect.
Lipid and glucose metabolism modulation
Cissus supplementation interacts with enzymes that digest fats and sugar — affecting both lipid and glucose metabolism. Mechanism explains the combined effects on weight, glucose tolerance, and lipid profile documented across trials. Multi-pathway metabolic effects support metabolic syndrome applications.
Appetite signaling modulation
Cissus has documented appetite-suppressing effects — though specific mechanisms remain incompletely characterized. May involve serotonergic effects or direct satiety signaling. Appetite reduction supports sustainable weight management by reducing caloric intake without willpower dependence.
Clinical trials
Double-blind randomized controlled trial evaluating Cissus quadrangularis supplementation in overweight and obese subjects. Foundational efficacy trial. Eligibility: BMI >25, waist circumference >85.5 cm. 8-week intervention with comprehensive metabolic assessment.
123 overweight and obese subjects with BMI 25.5-45.6, waist circumference 85.5-125 cm, weight 62.6-142 kg. 8-week intervention.
A proprietary Cissus quadrangularis formulation (not isolated Cissus) reduced body weight, central obesity, glucose, cholesterol and triglycerides versus placebo over 8 weeks. From a single industry-linked group and not independently replicated, so the result is preliminary and cannot be attributed to Cissus alone. Published in Lipids in Health and Disease.
Pilot study evaluating Cissus quadrangularis effects on exercise-induced joint pain and impairment in trained men. 8-week supplementation period. Published by Bloomer, Farney, McCarthy, Lee in The Physician and Sportsmedicine (small pilot study).
29 exercise-trained men. 8-week intervention.
Self-reported joint pain (WOMAC) fell about 31% from baseline over 8 weeks at 3,200 mg/day. This was an uncontrolled pilot with no placebo group (n=29), so the change cannot be separated from natural variation or expectation, and no clinical biomarkers changed. The authors called for a placebo-controlled trial to confirm it.
Randomized placebo-controlled trial evaluating Cissus quadrangularis for delaying bone loss in postmenopausal women with osteopenia. Published in Phytomedicine (Benjawan, Nimitphong, et al.).
Postmenopausal women with osteopenia. Randomized placebo-controlled design.
Over 24 weeks in 134 postmenopausal women with osteopenia, bone mineral density did not differ from placebo at any site. A bone-formation marker (P1NP) fell, suggesting slower bone remodeling, but this is a laboratory surrogate and no gain in bone density was measured. The primary bone outcome was null.